^
MET N375S
Salivary Gland Cancer
crizotinib + pazopanib
Sensitive
:
C3
Onco Targets Ther - 4d
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
cisplatin + doxorubicin hydrochloride + cyclophosphamide oral
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
cisplatin + vinorelbine tartrate
Sensitive
:
A2
NTRK2 fusion
Salivary Gland Cancer
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Salivary Gland Cancer
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Salivary Gland Cancer
entrectinib
Sensitive
:
A2
NTRK1 fusion
Salivary Gland Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Salivary Gland Cancer
entrectinib
Sensitive
:
A2
AR positive
Salivary Gland Cancer
leuprolide acetate
Sensitive
:
A2
AR positive
Salivary Gland Cancer
bicalutamide
Sensitive
:
A2
PD-L1 expression
Salivary Gland Cancer
pembrolizumab
Sensitive
:
C1
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive
:
C1
RET fusion
Salivary Gland Cancer
selpercatinib
Sensitive
:
C1
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive
:
C2
AR positive
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive
:
C3
PLIN2 expression
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive
:
C3
AKT1 E17K
Salivary Gland Cancer
AZD5363
Sensitive
:
C3
HER-2 expression
Salivary Gland Cancer
ARX788
Sensitive
:
C3
HRAS mutation
Salivary Gland Cancer
tipifarnib
Sensitive
:
C3
HER-2 amplification
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
HER-2 expression
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
PTEN expression
Salivary Gland Cancer
bicalutamide
Sensitive
:
C3
PTEN expression
Salivary Gland Cancer
trastuzumab
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our